Pfizer pneumonia shot helps HIV-infected patients (AEGiS) - Pfizer pneumonia shot helps HIV-infected patients
Reuters NewMedia - March 3, 2010 Kate Kelland
http://www.aegis.org/news/re/2010/RE100303.html

LONDON (Reuters) - Results of a trial of Pfizer's Prevnar 7 vaccine against a major cause of pneumonia and meningitis showed on Wednesday that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa.
British researchers who tested the shot in Malawi found it stopped 74 percent of recurrent cases of invasive pneumococcal disease (IPD) in patients infected with HIV, the human immunodeficiency virus that causes AIDS.
The results suggest the vaccine may benefit other high-risk adult patient groups, the researchers said, although the cost -- at around $40 per dose -- may pose problems in poor countries.
"This is the first trial to use a conjugate pneumococcal vaccine in an adult group and find clinical benefits," said Neil French of the London school of Hygiene and Tropical Medicine, who led the study.
"Since it works in patients with HIV infection ... it is likely to work in other adult groups, including the elderly and other at-risk groups."
Prevnar is a pneumococcal conjugate vaccine (PCV) designed to protect against infection with streptococcus pneumoniae bacteria, which can invade the blood stream and brain and cause invasive pneumococcal disease (IPD), in turn leading to the serious and often fatal illnesses of septicaemia and meningitis.
In HIV-infected patients, particularly in sub-Saharan Africa, the risk of developing IPD increases is between 30 and 100 times higher, the scientists said in their study in the New England Journal of Medicine.
Similar shots known as pneumococcal polysaccharide vaccines (PPVs) are currently used to protect adults in Britain and the United States, but have had limited success in HIV-infected adults and are not recommended for use in Africa.
Pfizer won approval last week for its updated version of the shot, Prevnar 13, which protects against 13 strains of streptococcus pneumoniae bacteria, as opposed to the seven tackled by the original.
The original Prevnar was introduced in 2000 and has annual sales of around $3 billion.
GlaxoSmithKline has a rival vaccine called Synflorix that acts against 10 strains, and Merck sells Pneumovax 23, which fights 23 strains and is the only vaccine of its type approved in the United States for adults.
Scientists tested the Prevnar 7 vaccine on almost 500 predominantly HIV-infected adults in Blantyre, Malawi.
Alongside their main finding, they also found the vaccine prevented disease even in HIV-infected people whose immune systems were very weak and who were starting to develop AIDS.
French described this effect as "remarkable," and said it was probably due to the vaccine's conjugate technology.
Polysaccharide vaccines consist of long chains of sugar molecules isolated from the infectious agent -- in this case, the pneumococcal bacteria. But to boost the shot's effect and make a conjugate vaccine, the sugar molecules can be bound to a "carrier" protein which magnifies the immune response.
"This gives hope for the possible use of conjugate technology in other vaccines targeting important HIV-associated bacterial infections," French wrote in the study.
(Editing by Greg Mahlich)
100303 RE100303

Copyright © 2010 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2010. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2010. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. [AEGiS]